Bosch JL, Hunink MG. 1997. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortailiac occlusive disease. Radiology, 204:87–96. Breuss JM, Cejna M, Bergmeister H, et al. 2002. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation, 105:633–8. Brull DJ, Montgomery HE, Sanders J, et al. 2001. Interleukin-6 gene – 174G>C and –572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol, 21:1457–63. Buffon A, Liuzzo G, Biasucci LM, et al. 1999. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol, 34:1512–21. Cejna M, Breuss JM, Bergmeister H, et al. 2002. Inhibition of neointimal formation after stent placement with adenovirus-mediated gene transfer of I kappa B alpha in the hypercholesterolemic rabbit model: initial results. Radiology, 223:702–8. Cejna M, Thurnher SA, Illiasch H, et al. 2001. PTA vs Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomised study. J Vasc Interven Radiol, 12:23–31. Cipollone F, Marini M, Fazia M, et al. 2001. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol, 21:327–34. Diegeler A, Thiele H, Falk V, et al. 2002. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med, 347:561–6. Dormandy JA, Rutherford B. 2000. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg, 31(1 Pt 2):S1–296. Duckers HJ, Boehm M, True AL, et al. 2001. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med, 7:693–8. Ernst E. 1993. Fibrinogen as a cardiovascular risk factor: interrelationship with infections and inflammation. Eur Heart J, 14:82–7. Exner M, Schillinger M, Minar E, et al. 2001. Heme oxygenase-1 microsatellite gene promoter polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther, 8:433–40. Exner M, Schillinger M, Minar E, et al. 2004. Interleukin 6 genotype and restenosis after balloon angioplasty: initial observation. Radiology, 231:839–44. Forrester JS, Fishbein M, Helfant R, et al. 1991. A paradigm for restenosis based on cell biological clues for the development of new preventive therapies. J Am Coll Cardiol, 17:758–69. Gallino A, Mahler F, Probst P, et al. 1984. Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation, 70:619–23. Glass CK, Witztum JL. 2001. Atherosclerosis: the road ahead. Cell, 104:503–16. Haverkate F, Thompson SG, Pyke SDM, et al. 1997. Production of C- reactive protein and risk of coronary events in stable and unstable angina. Lancet, 349:462–6. Heinrich J, Schulte H, Schönfeld R, et al. 1995. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost, 73:374–9. Ishikawa K, Sugawara D, Wang Xp, et al. 2001. Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Circ Res, 88:506–12. Jeans WD, Armstrong S, Cole SE, et al. 1990. Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. Radiology, 177: 559–64. Jukema JW, Kastelein JJ. 2000. Tailored therapy to fit individual profiles. Genetics and coronary artery disease. Ann N Y Acad Sci, 902:17–24. Kamijikkoku S, Murohara T, Tayama S, et al. 1998. Acute myocardial infarction and increased soluble intercellular adhesion molecule-1: a marker of vascular inflammation and risk of early restenosis? Am Heart J, 136:231–6. Vascular Health and Risk Management 2005:1(1) Inflammation and restenosis Kastrati A, Dirschinger J, Schomig A. 2000. Genetic risk factors and restenosis after percutaneous coronary interventions. Herz, 25:34–46. Kimpara T, Takeda A, Watanabe K, et al. 1997. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet, 100:145–7. Kornowski R, Hong MK, Tio FO, et al. 1998. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol, 31:224–30. Krepel VM, van Andel GJ, van Erp WF, et al. 1985. Percutaneous transluminal angioplasty of femoropopliteal artery: initial and long term results. Radiology, 156:325–8. Kuller LH, Tracy RP, Shaten J, et al. 1996. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol, 144:537–47. Libby P, Ridker P, Maseri A. 2002. Inflammation and atherosclerosis. Circulation, 105:1135–43. Liuzzo G, Biasucci L, Gallimore JR, et al. 1994. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med, 331:417–24. Lusis AJ. 2000. Atherosclerosis. Nature, 407:233–41. Maca T, Ahmadi R, Derfler K, et al. 1996. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis, 127: 27–34. Maines MD. 1988. Heme oxygenase: function, multiplicity, regulatory mechanisms and clinical application. FASEB J, 2:2557–68. Matsi PJ, Manninen HI, Vanninen RL, et al. 1994. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1–3-year follow-up. Radiology, 191: 727–33. Mendall MA, Patel P, Ballam L, et al. 1996. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 312:1061–5. Mickelson JK, Lakkis NM, Villarreal-Levy G, et al. 1996. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol, 28:345–53. Minar E, Pokrajac B, Ahmadi R, et al. 1998. Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. Radiology, 208:173–9. Minar E, Pokrajac B, Maca T, et al. 2000. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomised study. Circulation, 102:2694–9. Morice MC, Serruys PW, Sousa JE, et al. 2002. A randomised comparison of a sirolymus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 346:1773–80. O’Brian ER, Schwartz SM. 1994. Update of the biology and clinical study of restenosis. Trends Cardiovasc Med, 4:169–78. Ohtani K, Egashira K, Usui M, et al. 2004. Inhibition of neointimal hyperplasia after balloon injury by cis-element “decoy” of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther, 11: 126–32. Orford JL, Selwyn AP, Ganz P, et al. 2000. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol, 86(Suppl):6H–11H. Pepys MB. 1995. The acute phase response and C-reactive protein. In Weatherall DJ, Ledingham JGG, Warrell DA (eds). Oxford textbook of medicine, third edition. Oxford: Oxford Univ Pr. p 1527–33. Pepys MB, Baltz ML. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein (Review). Adv Immunol, 34:141–212. Pietersma A, Kofflard M, de Wit LE, et al. 1995. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation, 91:1320–5. Roguin A, Hochberg I, Nikolsky E, et al. 2001. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol, 87:330–2. 77